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Background: Hypoparathyroid patients often have a higher bone mineral density (BMD) than the general population. However, an 
increase in BMD does not necessarily correlate with a solid bone microstructure. This study aimed to evaluate the bone microstruc-
ture of hypoparathyroid patients by using hip structure analysis (HSA). 
Methods: Ninety-five hypoparathyroid patients >20 years old were enrolled and 31 of them had eligible data for analyzing bone ge-
ometry parameters using HSA. And among the control data, we extracted sex-, age-, and body mass index-matched three control 
subjects to each patient. The BMD data were reviewed retrospectively and the bone geometry parameters of the patients were ana-
lyzed by HSA. 
Results: The mean Z-scores of hypoparathyroid patients at the lumbar spine, femoral neck, and total hip were above zero (0.63±1.17, 
0.48±1.13, and 0.62±1.10, respectively). The differences in bone geometric parameters were site specific. At the femoral neck and 
intertrochanter, the cross-sectional area (CSA) and cortical thickness (C.th) were higher, whereas the buckling ratio (BR) was lower 
than in controls. However, those trends were opposite at the femoral shaft; that is, the CSA and C.th were low and the BR was high. 
Conclusion: Our study shows the site-specific effects of hypoparathyroidism on the bone. Differences in bone components, marrow 
composition, or modeling based bone formation may explain these findings. However, further studies are warranted to investigate 
the mechanism, and its relation to fracture risk. 
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INTRODUCTION
Hypoparathyroidism, the deficiency or absence of parathyroid 
hormone (PTH), is a unique condition; it is managed with calci-
um, active vitamin D, or dichlozid supplements [1], whereas 
most other conditions of hormone deficiencies are treated by re-
placing the deficient hormone itself. 
PTH is an important hormone for regulating calcium and 
phosphate homeostasis, and also plays a key role in bone re-
modeling. It increases bone resorption by stimulating the recep-
tor activator for nuclear factor κ B ligand (RANKL) expression 
of osteoblasts, osteocytes, and T cells [2,3], and when given in-
termittently with at a low dose, has been reported to have ana-
bolic effects on the bone [4]. The exact mechanism of this ana-
bolic effect is uncertain; however, presumably, it is induced by 
increasing insulin-like growth factor 1 and suppressing apopto-
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sis and sclerostin (SOST) expression [4].
The effects of a PTH excess or deficiency on the bone mineral 
density (BMD) have been described in previous studies. In case 
of hyperparathyroidism, the BMD is usually preserved at the 
lumbar spine where the trabecular bone is dominant. However, 
at the femur, where the cortical bone is dominant, the BMD is 
decreased and tunneling effects are noted, which lead to a high 
risk of fracture [5]. In contrast, patients with permanent hypo-
parathyroidism were reported to have higher BMD than do age- 
and sex-matched controls [6]. Takamura et al. [7] reported high-
er BMDs in postmenopausal women with postoperative tran-
sient hypoparathyroidism, and they attributed this finding to at-
tenuated bone turnover. However, as a high BMD does not nec-
essarily reflect high bone quality, the risk of fracture in patients 
with hypoparathyroidism is controversial [8-10]. Furthermore, 
studies on the quantitative and qualitative change of bone in hy-
poparathyroid patients and patients receiving treatment with 
PTH are lacking.
Recently, Cusano et al. [11] reported that cortical volumetric 
BMD was increased and cortical porosity was reduced in hypo-
parathyroid patients at the radius and tibia. However, despite the 
increased BMD and decreased cortical porosity, the ultimate 
stress and failure load were not changed compared with those in 
controls. Noteworthy, the authors reported a trend toward a de-
crease in cortical thickness (C.th) at the radius and the tibia even 
though the etiology for the decreased C.th in their hypoparathy-
roid cohort was unclear. Therefore, in this study, we measured 
bone geometric parameters by using hip structure analysis 
(HSA). Here, we find that there is a site-specific difference of 
bone geometry indices in patients with hypoparathyroidism. 
METHODS
Subjects
Hypoparathyroid patients >20 years old were enrolled. We de-
fined hypoparathyroidism as a state of low PTH level below the 
lower limits of normal (15 pg/mL) on at least two prior occa-
sions, and the use of calcium or vitamin D treatment to maintain 
a normal calcium level. Patients who had been receiving treat-
ment with bisphosphonates, estrogens, progestins, calcitonin, 
diuretics, statins, or methotrexate, which are agents that could 
affect bone metabolism, were excluded. Patients were also ex-
cluded if they had a diagnosis of diabetes, chronic kidney dis-
ease, Cushing’s syndrome, or other malignancies. Ninety-five 
patients with hypoparathyroidism were enrolled, and 31 females 
of them had eligible dual-energy X-ray absorptiometry (DXA) 
data for HSA. 
The Severance Hospital Institutional Review Board approved 
the study protocol, and no consent was given because the data 
were collected and analyzed anonymously. 
Control subjects
We collected the control data from a previous study by Kim et 
al. [12]. The study data comprise measurements of bone geome-
try of 3,580 Korean people who participated in the Fourth Kore-
an National Health and Nutrition Examination Survey. To com-
pare the bone geometry of these controls with those of the pa-
tients, normal subjects aged from 20 to 80 years were selected. 
From the collected data, we extracted three sex-, age-, and body 
mass index (BMI)-matched control subjects to each patient. 
Biochemical measurement
The serum calcium, phosphate, and intact PTH levels, which 
were measured at the time of BMD measurement, were re-
viewed. The serum concentration of intact PTH was measured 
by immunoradiometric assay (Nichols Institute Diagnostics, 
Sacramento, CA, USA). The reference rage of serum intact 
PTH was 15 to 65 pg/mL. 
Imaging evaluation
The BMD data were reviewed retrospectively. The BMD of hy-
poparathyroid patients had been measured at the lumbar spine, 
femoral neck, and total hip, and by using the same densitometer 
at the same center (DXA, Hologic Discovery A, Waltham, MA, 
USA). The Z-score was used for analysis because the subjects 
in this study had a wide range of age. Mean values and standard 
deviations (SD) for each decade from the Korean reference data 
were used to calculate Z-score as previously reported [13]. The 
bone geometry parameters of the patients and were analyzed 
with an HSA program included in APEX software of Hologic, 
as previously described [12,14,15]. For control subjects, their 
BMD and bone geometry were analyzed by using DXA scan 
(QDR 4500 A, Hologic, Bedford, MA, USA) and HSA pro-
gram, respectively, and we obtained their data from the study by 
Kim et al. [12]. By using HSA, the geometric properties of the 
cross section can be analyzed at specific locations of the femur 
[16]. Three sites at the proximal femur were evaluated: narrow 
neck, intertrochanter, and shaft. The narrow neck indicates the 
narrowest point of the femoral neck; the intertrochanter region 
is the bisector of the neck-shaft angle; and the femoral shaft is 
located 2 cm distal from the midpoint of the lesser trochanter 
[16,17]. The narrow neck and shaft region were modeled as cir-
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cular annuli with a cortical bone content of 60% and 100%, re-
spectively. In contrast, the intertrochanter region was modeled 
as an elliptical annulus with a cortical and trabecular bone con-
tent of 70% and 30%, respectively [15,17]. At each location, the 
cross-sectional area (CSA), cross-sectional moment of inertia 
(CSMI), C.th, section modulus (SM), and buckling ratio (BR) 
were measured. The CSMI indicates structural rigidity and the 
distribution of mass about the center of a structural element. SM 
is an index of the bending strength for maximum bending stress, 
and BR means relative thickness of the cortex reflecting cortical 
stability in buckling [16]. Those bone geometry indices of the 
patient group were compared with those of the age-, sex-, and 
BMI-matched control subjects.
Statistical analysis
All statistical analyses were performed with the SPSS version 
20.0 (IBM Co., Armonk, NY, USA) and GraphPad Prism 5 
(GraphPad Software Inc., San Diego, CA, USA). Values are ex-
pressed as mean±SD or medians with interquartile range. De-
scriptive statistics were used to show the Z-scores of the BMD 
of hypoparathyroid patients. Between-group differences of 
means of baseline variables and Z-scores were tested by un-
paired t tests. For geometric parameters, because of the small 
number of the subjects in each group, nonparametric Mann-
Whitney U tests were used. For all statistical analysis, P<0.05 
was considered statistically significant.
RESULTS
The baseline characteristics are shown in Table 1. The mean age 
of the hypoparathyroid patients was 53.89±13.51 years, and 
most of them were women (78.9%). Their calcium, PTH, and 
25-OH-vitamin D levels were below normal. Of those 95 pa-
tients with hypoparathyroidism, 74 patients had postsurgical 
hypoparathyroidism, and the others had idiopathic hypoparathy-
roidism such as immune-mediated parathyroid destruction or 
genetic disorders. The baseline characteristics were similar be-
tween the two groups except for disease duration, calcium level, 
and β-cross laps. The mean duration of the disease was signifi-
cantly longer in patients with postsurgical hypoparathyroidism 
Table 1. Baseline Characteristics of the Hypoparathyroid Population
Variable Hypoparathyroid patients (n=95)
Postsurgical hypoparathyroidism 
(n=74)
Idiopathic hypoparathyroidism 
(n=21)
P value
Age, yr 53.89±13.51 56.04±11.20 46.33±17.97 0.003
Sex, male/female 20/75 13/61 7/14 0.106
Height, cm 159.36±6.30 159.04±5.73 160.33±7.95 0.496
Weight, kg 59.72±9.48 59.96±8.93 59.00±11.30 0.737
BMI, kg/m2 23.52±3.54 23.73±3.57 22.87±3.49 0.424
Disease duration, yr 7.20±7.40 8.05±7.92 4.19±4.07 0.034
Calcium, mg/dL 7.31±1.35 7.56±1.22 6.37±1.47 0.003
Phosphate, pg/mL 4.81±1.14 4.75±1.13 5.03±1.15 0.351
BUN, mg/dL 15.19±6.99 15.42±7.33 14.33±5.61 0.550
Cr, mg/dL 1.38±5.19 1.54±5.84 0.82±0.21 0.594
Alkaline phosphatase, IU/L 56.44±21.07 55.57±20.72 59.63±22.61 0.459
24-Hour urine calcium, mg/day 166.09±123.76 159.66±126.39 186.16±121.00 0.606
PTH, pg/mL 9.47±5.31 9.32±5.01 10.03±6.44 0.604
25-OH-vitamin D, ng/mL 25.02±10.37 25.65±10.36 22.59±10.33 0.268
β-Cross laps, ng/mL 0.24±0.18 0.27±0.18 0.15±0.15 0.042
Osteocalcin, ng/mL 13.59±6.19 14.18±6.40 10.97±4.65 0.220
Calcium on treatment, mg 1,063.40±688.04 1,033.07±753.42 1,154.40±446.31 0.559
Calcitriol on treatment, μg 0.56±0.32 0.57±0.34 0.54±0.26 0.779
Cholecalciferol on treatment, IU 1,733.33±1,149.05 1,806.45±1,197.20 1,527.27±1,024.78 0.496
Values are expressed as mean±SD. 
BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; PTH, parathyroid hormone.
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and calcium and β-cross laps were significantly lower in the id-
iopathic group.
The mean Z-scores of hypoparathyroid patients were above 
zero at all sites where BMD was measured—lumbar spine, fem-
oral neck, and total hip (0.63±1.17, 0.48±1.13, and 0.62±1.10, 
respectively) (Fig. 1A). The mean value of BMD was slightly 
higher at the lumbar spine than at the femoral neck or total hip; 
however, no statistical significance was found. We also com-
pared the BMD according to the etiology of the disease, and 
there was no difference between the two groups (Fig. 1B).
The difference in bone geometry between the patient group 
and the control group was analyzed at three sites (femoral neck, 
intertrochanter, and femoral shaft) for five indexes (CSA, CSMI, 
SM, C.th, and BR). Thirty-one females had eligible data for ana-
lyzing bone geometry. The number of patients in each age group 
was four (age 30 to 39 years), six (age 40 to 49 years), eight (age 
50 to 59 years), eight (age 60 to 69 years), and five (age 70 to 79 
years) (Table 2). We matched three control female subjects to 
each patient, and the number of controls for each age group was 
12, 18, 24, 24, and 15, respectively. The mean age of control 
subjects was 55.45±12.50 years and their mean BMI was 
23.11±3.11 kg/m2. In HSA, although the statistical significance 
varied within the age groups, we found a similar trend of indices 
in the patient group (Fig. 2). At the femoral neck and intertro-
chanter, the CSA and C.th were higher, whereas the BR was 
lower than those of the control subjects. Of interest, those find-
ings for the CSA, C.th, and BR were inversely noted at the femo-
ral shaft. At the femoral shaft, the CSA and C.th were low, 
whereas BR was high. Although the trend of the CSA was not 
statistically significant, the C.th and BR had a significant trend in 
the 40 to 49 and 70 to 79 years age groups. In patients with idio-
pathic hypoparathyroidism, the same trend was noted (Fig. 2, 
cross). In addition, the CSMI and SM were higher at the intertro-
chanter in hypoparathyroid patients group; however, this trend 
was not found at the femoral neck (Table 2). Of note, at femoral 
neck, CSMI was higher in age group of 30 to 39 and 70 to 79, 
whereas lower in age group of 40 to 49, 50 to 59, and 60 to 69. 
However as it was only significant in age group of 50 to 59 and 
60 to 69, we may need further data to make any conclusive ex-
planation. 
DISCUSSION
In this cross-sectional study, we showed that bone geometric 
parameters differ depending on the site. It is well known that 
hypoparathyroid patients have a higher BMD than the general 
population; however, their bone geometric characteristics have 
not been well understood. This study provides a better under-
standing of the bone structure of hypoparathyroid patients.
PTH has a crucial role in regulating bone remodeling. It in-
duces osteoclastogenesis by stimulating osteoblasts and subse-
quently, the bone matrix is resorbed and calcium is released 
[18]. In case of a low level of PTH, bone remodeling is sus-
pended and, thereby, the bone mass is increased. This idea has 
been supported by previous studies. A study of 33 hypoparathy-
roid patients showed that the patients had a higher BMD at the 
lumbar spine and proximal femur than did the control group 
[19]; other studies also reported similar results [6,20]. However, 
whether increased BMD has a protective effect against fractures 
in hypoparathyroid patients, as it has in the general population, 
is uncertain. According to Underbjerg et al. [8] increased BMD 
in hypoparathyroidism has a protective effect against fractures 
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at the upper extremities; however, some other studies could not 
find any protective role, and even revealed an increased risk of 
fracture [9,10]. These inconsistent results raised the question 
about the bone structure in hypoparathyroid patients. A previous 
study with iliac biopsy noted that the bone structure and dynam-
ic properties are markedly atypical in hypoparathyroid patients 
[19]. However, these studies were limited by the small number 
of evaluated patients and their use of an invasive procedure that 
cannot be easily applicable in clinics. In this study, the BMD of 
95 hypoparathyroid patients was reviewed, and the bone geom-
etry of 31 patients was analyzed by using HSA.
On baseline characteristics, the mean duration of the disease 
differs between the postsurgical group and idiopathic group, 
which might be due to the period of nondetection of the disease. 
Postsurgical PTH deficiency is usually detected during the early 
stage of disease, because patients usually obtain regular check-
ups after the operation. On the other hand, patients with idio-
pathic hypoparathyroidism usually seek medical attention only 
after they develop symptoms of hypocalcemia; hence, the dis-
ease is usually recognized late. Therefore, the actual duration of 
disease in the idiopathic hypoparathyroidism group could have 
been longer than what has been stated. Calcium and β-cross laps 
were significantly lower in the idiopathic group, and again it 
could be explained by the longer nontreatment period before the 
Table 2. Bone Geometric Parameters of Hypoparathyroid Patients and Controls
Variable Age, yr
Femoral neck Intertrochanter Femoral shaft
Hypoparathyroid 
patients Control
Hypoparathyroid 
patients Control
Hypoparathyroid 
patients Control
CSA, cm2 30–39 2.94 (2.65–3.27)a 2.59 (2.50–2.85) 5.56 (4.92–5.94) 4.50 (4.07–5.20) 3.76 (3.47–4.04) 3.77 (3.53–4.09)
40–49 2.99 (2.80–3.60) 2.96 (2.84–3.07) 5.40 (4.34–6.03) 4.87 (4.10–5.10) 3.90 (4.77–4.00) 4.10 (3.82–4.55)
50–59 2.59 (2.46–3.01) 2.60 (2.47–2.94) 4.74 (4.26–5.65) 4.46 (4.03–5.17) 3.61 (3.47–4.18) 4.11 (3.91–4.38)
60–69 3.17 (3.13–3.28) 3.05 (2.50–3.17) 4.55 (4.22–5.03)b 3.84 (3.17–4.09) 3.80 (3.40–4.13) 3.96 (3.59–4.19)
70–79 2.59 (2.25–2.65)a 2.07 (1.80–2.25) 4.26 (4.16–5.69)a 3.34 (2.68–3.71) 3.19 (3.08–3.62) 3.57 (3.20–3.96)
CSMI, cm2 30–39 2.43 (2.24–2.59) 2.11 (1.82–2.43) 14.48 (11.19–16.21) 10.09 (8.75–10.82) 2.93 (2.59–3.27) 2.47 (2.10–2.69)
40–49 2.65 (2.37–3.28) 2.85 (2.64–3.07) 14.77 (11.48–19.06) 10.52 (8.95–12.65) 3.35 (2.79–4.02) 3.01 (2.58–3.22)
50–59 1.84 (1.71–2.18)a 2.47 (2.17–2.64) 13.57 (12.78–14.71)a 11.21 (9.11–13.56) 3.17 (2.96–3.49) 2.87 (2.54–3.45)
60–69 1.95 (1.73–2.38)c 2.99 (2.77–3.09) 12.25 (11.58–14.90)c 10.44 (8.08–11.19) 3.68 (2.60–4.07) 3.28 (2.83–3.69)
70–79 1.84 (1.81–2.03) 1.56 (1.36–1.88) 9.82 (9.73–16.53)a 7.50 (5.94–8.63) 3.20 (3.12–3.23) 2.68 (2.24–3.33)
SM, cm3 30–39 1.40 (1.16–1.55) 1.21 (1.13–1.42) 4.56 (3.72–4.87) 3.35 (2.79–3.73) 2.02 (1.76–2.16) 1.81 (1.61–1.97)
40–49 1.54 (1.33–1.76) 1.36 (1.30–1.51) 4.55 (3.59–5.26) 3.55 (3.10–4.05) 2.13 (2.04–2.55) 2.10 (1.88–2.22)
50–59 1.35 (1.18–1.50) 1.33 (1.24–1.47) 4.40 (3.86–4.79) 3.74 (3.23–4.35) 2.11 (1.98–2.21) 2.07 (1.86–2.28)
60–69 1.14 (1.06–1.29) 1.16 (0.95–1.27) 3.90 (3.66–4.31)b 3.34 (2.69–3.56) 2.23 (1.83–2.53) 2.25 (1.92–2.39)
70–79 1.10 (0.91–1.14) 0.96 (0.80–1.03) 3.18 (2.85–4.96)a 2.49 (1.97–2.94) 2.09 (2.05–2.30) 1.80 (1.55–2.23)
C.th, cm 30–39 0.21 (0.19–0.22)a 0.18 (0.16–0.20) 0.49 (0.43–0.50) 0.44 (0.39–0.45) 0.49 (0.45–0.58) 0.61 (0.57–0.68)
40–49 0.19 (1.18–0.20) 0.18 (0.15–0.20) 0.42 (0.37–0.46) 0.41 (0.34–0.45) 0.50 (0.48–0.51)b 0.61 (0.55–0.73)
50–59 0.16 (0.14–0.19) 0.18 (0.15–0.19) 0.41 (0.34–0.46) 0.39 (0.33–0.45) 0.49 (0.44–0.59)a 0.57 (0.55–0.64)
60–69 0.17 (0.15–0.18)a 0.15 (0.13–0.16) 0.37 (0.34–0.40)b 0.31 (0.25–0.33) 0.47 (0.45–0.54) 0.50 (0.45–0.56)
70–79 0.17 (0.14–0.18)a 0.12 (0.11–0.14) 0.35 (0.33–0.45)b 0.28 (0.23–0.30) 0.46 (0.45–0.48) 0.48 (0.44–0.54)
BR 30–39 7.70 (7.40–8.25)a 10.16 (8.86–11.54) 6.45 (6.30–6.70) 6.90 (6.05–8.02) 3.10 (2.55–3.45) 2.25 (1.89–2.46)
40–49 9.15 (8.90–10.20) 10.61 (8.77–12.37) 8.10 (7.90–8.80) 7.46 (5.87–8.93) 3.20 (3.00–3.30)b 2.20 (1.97–2.68)
50–59 9.25 (8.75–11.00) 10.60 (8.60–11.97) 8.15 (6.85–9.30) 7.42 (6.64–9.44) 3.00 (2.55–3.65)a 2.41 (2.20–2.70)
60–69 9.75 (9.30–10.35)c 12.65 (11.60–14.10) 9.05 (8.00–10.20) 10.47 (9.39–12.18) 3.20 (3.00–3.45) 3.03 (2.65–3.40)
70–79 11.80 (10.8–13.10) 14.65 (12.88–15.39) 9.70 (7.40–9.90)a 11.85 (9.74–13.31) 3.40 (3.10–3.50) 3.06 (2.73–3.17)
Values are expressed as median (interquartile range).
CSA, cross-sectional area; CSMI, cross-sectional moment of inertia; SM, section modulus; C.th, cortical thickness; BR, buckling ratio.
aP<0.05; bP<0.01; cP<0.001 vs. control. 
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diagnosis. Regarding lower β-cross laps, genetic mutation or 
autoimmune factor of idiopathic hypoparathyroidism could play 
a role in suppressing bone turnover. However, role of genetic or 
autoimmune factor regarding bone remodeling was not dealt in 
this study, which can be a limitation of this study. 
The mean Z-scores in hypoparathyroid patients were above 
zero, which indicate higher BMDs than those in sex- and age-
matched Korean population. In terms of the sites, the Z-score of 
the lumbar spine was slightly higher than that of the femoral 
neck or total hip; however, no significant difference was found. 
Furthermore, when the patients were grouped according to dis-
ease etiology, there was no difference in the Z-score between 
the groups, which is consistent with a previous study [6]. Of the 
95 patients, the DXA data of 31 patients were used to analyze 
bone geometry by using the HSA program, because we only in-
cluded female data and the HSA program was available only af-
ter 2011. The bone geometry of those 31 patients was compared 
with that of the control subjects. The structural indices including 
C.th, CSA, CSMI, SM, and BR were analyzed. Those parame-
ters were previously demonstrated to be risk factors for fracture 
[21]. It was reported that subjects with a history of fracture had 
lower CSA, C.th, CSMI, and SM, and higher BR than subjects 
without a history of fracture. In this regard, if hypoparathyroid-
ism increases the BMD with a lower risk of fracture similar to 
the general population, we should have seen higher CSA, C.th, 
CSMI, and SM, and lower BR in the patient group. Interesting-
ly, the results were rather different depending on the measure-
ment site. At the femoral neck and intertrochanter, the bone ge-
ometry parameters showed a similar trend, as expected; the C.th 
and CSA were high, whereas the BR was low. However, at the 
femoral shaft, the C.th and CSA were found to be lower, and the 
BR higher, than those in the control subjects.
Fig. 2. Bone geometric parameters of the control subjects and hypoparathyroid patients. The values of the sex-, age-, and body mass index-
matched control subjects are depicted as lines shown as mean±SD; those of the hypoparathyroid patients are shown as circles (postsurgical 
hypoparathyroidism) or cross (idiopathic hypoparathyroidism). 
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The specific reason for the different trends at different sites is 
unclear. Previously, it was illustrated that increased BMD in hy-
poparathyroid patients differed depending on the site [6]. Al-
though it was not statistically significant, increased BMD was 
more prominent at the lumbar spine than at the femoral neck. 
We assumed that this difference might be attributed to the dif-
ference in bone composition. In the same context, the site-spe-
cific difference of bone geometry parameters can also be due to 
inconsistent bone structure. The lumbar spine and femoral neck 
have considerable amount of trabecular bone, whereas the fem-
oral shaft mostly consists of cortical bone [22]. In this study, at 
the femoral neck where the proportion of trabecular bone is esti-
mated as 40% [23], the C.th in hypoparathyroid patients was 
higher; however, this finding was not observed at the femoral 
shaft, which is mostly composed of cortical bone. As mentioned 
above, the increased BMD in hypoparathyroid patients resulted 
from decreased bone turnover and remodeling; thereby, it af-
fects mostly the trabecular bone. At the femoral neck where tra-
becular bone is abundant, the excavated cavities at the trabecu-
lar bone adjacent to the cortical bone receive infilling, which 
can lead to thicker cortical bone. In contrast, the femoral shaft 
mostly consists of cortical bone, which means less chance of 
being affected by decreased bone turnover. Hence, it is less like-
ly to accrue C.th. We also assumed that different marrow com-
positions among locations could be a potential factor for differ-
ent reactions to PTH deficiency. At birth, the red marrow occu-
pies most of the skeletal bones except epiphyses and apophyses. 
During growth, the red marrow becomes confined to the axial 
skeleton, and the femoral neck is the only site in the femur 
where residual red marrow exists. The yellow marrow replaces 
the red marrow in the rest of the femur [24]. As it is mainly 
made of fat tissues, it is plausible that the bone part consisting 
of yellow marrow does not actively respond to bone modeling. 
Finally, less modeling-based bone formation (MBF) would in-
duce the site-specific response to PTH deficiency. A well-
known antiresorptive agent, denosumab, was reported to con-
tinuously increase BMD by maintaining MBF [25]. What was 
intriguing about this finding was that this effect was only con-
fined to some part of the bone—the superior endocortex and in-
ferior periosteum of the femoral neck. These two sites are where 
mechanical loading is increased. Because PTH deficiency also 
reduces bone turnover and remodeling like denosumab does, we 
propose that PTH also maintains MBF only at sites where load-
ing is increased, like the femoral neck in this study. With the 
above-mentioned mechanisms, we could partly explain why the 
geometric indices at the femoral neck and intertrochanter 
changed as we expected. However, the changes at the femoral 
shaft are still unclear. A similar result was reported in a recent 
study [11] that analyzed the skeletal microstructure of the distal 
radius and tibia by using high-resolution peripheral quantitative 
computed tomography, and the authors found a trend toward a 
decline in C.th. An underlying disease and lower physical activ-
ity level of the patients were raised as factors for a decreased 
C.th; however, the exact mechanism is still uncertain.
This study has some limitations. Although we analyzed BMD 
in 95 hypoparathyroid patients, which, to our knowledge, is the 
largest number of study patients, only female patients (n=31) 
were evaluated for bone geometric parameters. Moreover, the 
study population might not be enough to represent all hypopara-
thyroid patients. Second, bone biopsy was not assessed. In the 
scan images, edge margins are often blurred, and there may be 
difficulties in differentiating cortical bone from trabecular bone 
[26]. Lastly, this was a retrospective study. However, a prospec-
tive study is difficult to perform because the exact onset of hy-
poparathyroidism is difficult to define.
In conclusion, we demonstrated that hypoparathyroidism af-
fects the site of bone remodeling specifically. Further studies are 
needed to investigate the exact mechanism of the site-specific 
response of the bone to PTH deficiency. 
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